home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Collection of Education
/
collectionofeducationcarat1997.iso
/
HEALTH
/
MED9602.ZIP
/
M9620372.TXT
< prev
next >
Wrap
Text File
|
1996-02-26
|
2KB
|
32 lines
Document 0372
DOCN M9620372
TI [New anti-HIV drug which binds the oligosaccharides of HIV envelope
glycoprotein]
DT 9602
AU Mizuochi T; Nakata M; Department of Applied Chemistry, Tokai University.
SO Nippon Rinsho. 1995 Sep;53(9):2340-9. Unique Identifier : AIDSLINE
MED/96008339
AB The virion surface of the human immunodeficiency virus (HIV-1) is
covered with an envelope glycoprotein gp120. Study of the
oligosaccharide structures of gp120 suggests that the high mannose type
of oligosaccharides are essential for HIV-1 infection. Pradimicin A, an
antifungal antibiotic isolated from Actinomadura hibisca, and the
derivative BMY-28864 have the ability to inhibit HIV-1 infection in
vitro. The inhibitory effect was suppressed by addition of high mannose
type oligosaccharides of gp120. BMY-28864 bound directly to gp120,
mannose-BSA, and neoglycolipids containing high mannose type
oligosaccharides but not to natural mammalian glycoproteins. The binding
was Ca2+ dependent and was inhibited by mannose. BMY-28864 is a unique
carbohydrate-binding antibiotic which has never been reported. It is
possible to block HIV-1 infection by targeting oligosaccharide chains of
the envelope glycoprotein.
DE *Acquired Immunodeficiency Syndrome Animal Antibiotics,
Anthracycline/*METABOLISM Antibiotics, Antifungal/*METABOLISM
Calcium/PHYSIOLOGY Carbohydrate Sequence Drug Design English Abstract
Human HIV Envelope Protein gp120/*METABOLISM Molecular Sequence Data
Protein Binding JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).